ASK REDCHAT ANYTHING ABOUT NEUROGENE INC.
Neurogene Inc. (NASDAQ: NGNE)
Listen to this Section
$27.49
+0.0100
(
+0.04% )
0.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NGN-401DetailsRare genetic disease, Rett syndrome |
Phase 1/2 |
| NGN-101DetailsRare genetic disease, Batten Disease |
Phase 1/2 |
Market Data
|
| Open |
$27.49 |
| Previous Close |
$27.48 |
| Volume |
0.0K |
| Market Cap |
$414.33M |
| Day Range |
$27.41 - $27.47 |
| 52 Week Range |
$14.65 - $37.27 |
| Shares Outstanding |
15.80M |
| Change % |
+0.04% |
| Net Change |
▲ 0.0100 |
| Insider Ownership |
0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2023 |
| Country | Canada |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-240,683.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-11-27 |
Buy |
20748.00 |
Samsara BioCapital GP, LLC |
| 2024-11-25 |
Buy |
47500.00 |
McMinn Rachel |
| 2024-11-25 |
Buy |
24000.00 |
Cvijic Christine Mikail |
| 2024-06-17 |
Sale |
-7700.00 |
BAFFI ROBERT |
| 2024-06-17 |
Sale |
-7700.00 |
Woods Robert Keith |
| 2024-06-17 |
Sale |
-7700.00 |
PALEKAR ROHAN |
| 2024-06-17 |
Sale |
-7700.00 |
Freedland Cory S. |
| 2024-06-17 |
Sale |
-7700.00 |
Noonberg Sarah B. |
| 2024-03-14 |
Sale |
-31903.00 |
Cvijic Christine Mikail |
| 2024-03-14 |
Sale |
-93282.00 |
McMinn Rachel |